SCHEDULE 13G/A: Deep Track Capital Discloses 9.65% Stake in Ocular Therapeutix

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a 9.65% beneficial ownership stake in Ocular Therapeutix, Inc., totaling 15,458,138 shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 15,458,138 shares of Ocular Therapeutix, Inc. common stock.
• This represents 9.65% of the company's outstanding common stock.
• The reported shares include 1,163,718 pre-funded warrants exercisable into common stock, subject to a 9.99% beneficial ownership limitation.
• The calculation of the percentage is based on 160,185,963 total common shares, which includes 159,022,245 common shares outstanding as of February 27, 2025 (per the issuer's Form 10-K filed March 3, 2025) plus the 1,163,718 pre-funded warrants.
• The filing indicates shared voting and dispositive power over all 15,458,138 shares.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of a significant beneficial ownership stake. While neutral in tone, the continued large holding by an institutional investor can be seen as a mild positive signal of confidence in the company, hence a slightly above neutral score.

Positives

• A significant institutional investor, Deep Track Capital, maintains a substantial stake (9.65%) in Ocular Therapeutix, indicating continued confidence or strategic interest in the company.
• The inclusion of pre-funded warrants suggests a flexible investment structure that allows for potential future conversion while managing beneficial ownership limits.

Risks

• The beneficial ownership limitation of 9.99% on pre-funded warrants means that the holder cannot exercise warrants if it would cause them to exceed this threshold, potentially limiting their ability to fully convert their investment into common stock at certain times.
• While the filing states the securities are not held for control purposes, the large stake could still be perceived as a potential influence on corporate governance or strategic direction, even if passive.

Future Outlook

NA

Management Comments

• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing indicates a significant institutional investment in Ocular Therapeutix, a company operating in the biotechnology sector, specifically in ophthalmology. Such substantial stakes by specialized funds like Deep Track Capital are common in the biotech industry, where long-term investment in promising drug development or medical device companies is typical. The 9.65% stake suggests a notable position within the company's shareholder base, potentially signaling confidence in its pipeline or market position relative to its peers.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake provides transparency regarding the company's ownership structure and may influence investor perception and confidence.
• Company Management: The presence of a large institutional investor may lead to increased scrutiny or engagement regarding strategic decisions, even if the investor disclaims intent to influence control.

Key Dates

Keywords

Ocular Therapeutix, Deep Track Capital, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, Biotechnology, Healthcare